Skip to content
value.today
Cognition Therapeutics, Inc. logo

Cognition Therapeutics, Inc.

CGTX
$70 Mmarket cap on Oct 30, 2026+11.7% since Jan 2024
Compare
World rank
#20,053
Revenue
—
For year ending December-2025
Net income
$-23 M
SEC filing
Employees
14
As of March 1, 2026
SEC filing

Cognition Therapeutics, Inc. in brief

Cognition Therapeutics, Inc. is a listed company in the Biotechnology industry, based in Purchase, New York, USA. Its market value was $70 M on 30 October 2026, which makes it the 20,053rd largest listed company in the world and the 3,705th largest in the USA on this site. It employs about 14 people and Lisa Ricciardi is its chief executive. Its shares trade under the symbol CGTX (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Cognition Therapeutics, Inc.

We are a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system, or CNS, and retina. Currently available therapies for these diseases are limited, with many diseases having no approved therapies or treatments. Our goal is to develop disease-modifying treatments for patients with these degenerative disorders.

Our lead product candidate, zervimesine, also known as CT1812, is an orally delivered, small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins including β-amyloid, or Aβ and ɑ-synuclein. These and similar protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer’s disease, or AD, and dementia with Lewy bodies, or DLB.

From the company's annual report filed with the US SEC: read the report

Cognition Therapeutics, Inc. timeline

3 events, 2009–2021
  1. 2009
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2010
  4. ✎
    Renamed Cognition Therapeutics Inc
    Formerly Cognition Theraputics Inc.
  5. 2021
  6. 🔔
    Initial public offering on Nasdaq
    Final prospectus filed with the SEC on 12 October 2021; shares registered for exchange trading on 6 October 2021.

Events of Cognition Therapeutics, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$34 M$69 M$103 M$137 M2023202420252026

World rank over time

▲ up 1,133 places since 2022
2022-01-07: #21226#21,22620222022-12-25: #23653#23,65320222023-07-30: #25184#25,18420232024-01-05: #23815#23,81520242026-03-08: #10105#10,10520262026-08-01: #17487#17,48720262026-10-13: #19591#19,59120262026-10-30: #20093#20,0932026

Rank in USA: #4,217 (Jan 2022) · #4,568 (Dec 2022) · #4,727 (Jul 2023) · #3,947 (Jan 2024) · #1,957 (Mar 2026) · #3,439 (Aug 2026) · #3,606 (Oct 2026) · #3,709 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
2.1×
Free cash flow yield
-40.5%
Net margin
—
Operating margin
—
Return on equity
-68.5%
Liabilities / assets
29.2%
Profit per employee
$-1.7 M

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2020: revenue —, net income $-8M—FY20Fiscal year ending Dec 2021: revenue —, net income $-12M—FY21Fiscal year ending Dec 2022: revenue —, net income $-21M—FY22Fiscal year ending Dec 2023: revenue —, net income $-26M—FY23Fiscal year ending Dec 2024: revenue —, net income $-34M—FY24Fiscal year ending Dec 2025: revenue —, net income $-23M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-48M$-23M—
Dec 2024——$-54M$-34M—
Dec 2023——$-51M$-26M—
Dec 2022——$-44M$-21M—
Dec 2021——$-29M$-12M—
Dec 2020——$-17M$-8M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-25M——$-0.32—
Dec 2024$-28M$0M$-28M$-0.86—
Dec 2023$-16M$0M$-16M$-0.86—
Dec 2022$-19M$0M$-19M$-0.91—
Dec 2021$-4M$0M$-4M$-3.13—
Dec 2020$-3M$0M$-3M$-23.76—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-8M—Dec ’24Three months to Mar 2025: revenue —, net income $-8M—Mar ’25Three months to Jun 2025: revenue —, net income $-7M—Jun ’25Three months to Sep 2025: revenue —, net income $-5M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-3M—Dec ’25Three months to Mar 2026: revenue —, net income $-5M—Mar ’26Three months to Jun 2026: revenue —, net income $-4M—Jun ’26Three months to Sep 2026: revenue —, net income $-4M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-4M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Cognition Therapeutics, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-48 M
Net income
$-23 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$48 M
Total liabilities
$14 M
Total equity
$34 M

As of December-2025

Top 78 institutional investors in Cognition Therapeutics, Inc.#

As of Sep 30, 2026
78 institutions held 22.1 M shares (about 23.3% of the shares outstanding) on Sep 30, 2026. The ten largest hold 19.9%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Cognition Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1BIOS Capital Management, LP6,000,0000 (0.00%)6.31%$6 MNov 13, 2026
2DAVENPORT & Co LLC4,248,410-11,101 (-0.26%)4.47%$4 MOct 14, 2026
3Vanguard Capital Management LLC3,438,7750 (0.00%)3.62%$3 MNov 13, 2026
4BlackRock, Inc.1,253,474-8,519 (-0.68%)1.32%$1 MNov 13, 2026
5Chescapmanager LLC997,0290 (0.00%)1.05%$1 MNov 13, 2026
6Geode Capital Management, LLC911,526+1,520 (+0.17%)0.96%$1 MNov 6, 2026
7Renaissance Technologies LLC587,171-106,117 (-15.31%)0.62%$1 MNov 12, 2026
8Hilton Capital Management, LLC548,9500 (0.00%)0.58%$1 MNov 12, 2026
9Vanguard Fiduciary Trust Co508,2200 (0.00%)0.53%$0 MNov 13, 2026
10CM Management, LLC425,000-25,000 (-5.56%)0.45%$0 MNov 12, 2026
11Sigma Planning Corp364,765+2,500 (+0.69%)0.38%$0 MOct 23, 2026
12State Street Corp348,9830 (0.00%)0.37%$0 MNov 12, 2026
13Tocqueville Asset Management L.P.230,500-90,000 (-28.08%)0.24%$0 MNov 13, 2026
14Dauntless Investment Group, LLC207,714-163,987 (-44.12%)0.22%$0 MNov 16, 2026
15American Financial Group Inc205,0000 (0.00%)0.22%$0 MNov 12, 2026
16Northern Trust Corp178,2020 (0.00%)0.19%$0 MNov 16, 2026
17Susquehanna International Group, LLP152,114New0.16%$0 MNov 16, 2026
18Texas Capital Bank Wealth Management Services Inc143,2960 (0.00%)0.15%$0 MNov 9, 2026
19Charles Schwab Investment Management Inc84,9400 (0.00%)0.09%$0 MNov 16, 2026
20Corient Private Wealth LP81,287+3,061 (+3.91%)0.09%$0 MNov 16, 2026
21Voss Capital, LP71,512-103,488 (-59.14%)0.08%$0 MNov 16, 2026
22Marshall Wace, LLP71,065New0.07%$0 MNov 13, 2026
23Morgan Stanley68,373+40,500 (+145.30%)0.07%$0 MNov 13, 2026
24McAdam, LLC59,004-5,549 (-8.60%)0.06%$0 MOct 21, 2026
25Fca Corp /TX52,5360 (0.00%)0.06%$0 MNov 12, 2026
Show all 78: investors 26 to 78
Institutional investors 26 to 78 in Cognition Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Jones Financial Companies Lllp50,661+10,017 (+24.65%)0.05%$0 MNov 13, 2026
27BlueStem Wealth Partners, LLC50,000New0.05%$0 MNov 13, 2026
28Empirical Financial Services, LLC d.b.a. Empirical Wealth Management48,0000 (0.00%)0.05%$0 MOct 27, 2026
29Lido Advisors, LLC46,149New0.05%$0 MNov 4, 2026
30Bangor Savings Bank40,5190 (0.00%)0.04%$0 MOct 6, 2026
31Essex Financial Services, Inc.40,0000 (0.00%)0.04%$0 MNov 13, 2026
32StoneX Group Inc.30,945New0.03%$0 MNov 3, 2026
33Spark Investment Management LLC30,200New0.03%$0 MNov 13, 2026
34Gabelli Funds LLC30,0000 (0.00%)0.03%$0 MNov 12, 2026
35Bryn Mawr Trust Advisors, LLC29,0500 (0.00%)0.03%$0 MNov 4, 2026
36Citizens Financial Group Inc/ri27,358+13,679 (+100.00%)0.03%$0 MOct 23, 2026
37HighTower Advisors, LLC26,5000 (0.00%)0.03%$0 MNov 10, 2026
38Private Management Group Inc24,0000 (0.00%)0.03%$0 MNov 4, 2026
39Vanguard Global Advisers, LLC23,6410 (0.00%)0.02%$0 MNov 13, 2026
40CWA Asset Management Group, LLC23,0000 (0.00%)0.02%$0 MOct 19, 2026
41Virtu Financial LLC22,742-60,692 (-72.74%)0.02%$0 MNov 17, 2026
42Creative Planning22,2000 (0.00%)0.02%$0 MNov 2, 2026
43XTX Topco Ltd21,022-57,449 (-73.21%)0.02%$0 MNov 16, 2026
44Cetera Investment Advisers20,830+980 (+4.94%)0.02%$0 MNov 13, 2026
45Vestmark Advisory Solutions, Inc.20,080+10,040 (+100.00%)0.02%$0 MNov 16, 2026
46GAMCO Investors, Inc. Et Al20,0000 (0.00%)0.02%$0 MNov 12, 2026
47Rockefeller Capital Management L.P.19,2310 (0.00%)0.02%$0 MNov 13, 2026
48Northwestern Mutual Wealth Management Co17,4670 (0.00%)0.02%$0 MNov 13, 2026
49Focus Partners Wealth17,2500 (0.00%)0.02%$0 MNov 12, 2026
50Mercer Global Advisors Inc /adv15,9510 (0.00%)0.02%$0 MNov 16, 2026
51Bank of New York Mellon Corp13,4620 (0.00%)0.01%$0 MNov 5, 2026
52UBS Group AG13,145-205,391 (-93.98%)0.01%$0 MNov 10, 2026
53Liberty Wealth Management LLC13,000New0.01%$0 MNov 13, 2026
54Two Sigma Securities, LLC11,748New0.01%$0 MNov 16, 2026
55Bradley Foster & Sargent Inc/ct11,7220 (0.00%)0.01%$0 MNov 16, 2026
56Vanguard Personalized Indexing Management, LLC11,433-162 (-1.40%)0.01%$0 MNov 16, 2026
57Raymond James Financial Inc11,000-39,850 (-78.37%)0.01%$0 MNov 12, 2026
58Chicago Partners Investment Group LLC10,9090 (0.00%)0.01%$0 MOct 27, 2026
59Captrust Financial Advisors10,377New0.01%$0 MNov 12, 2026
60Elevation Point Wealth Partners, LLC10,0400 (0.00%)0.01%$0 MNov 5, 2026
61MML Investors Services, LLC10,0180 (0.00%)0.01%$0 MNov 13, 2026
62Retirement Planning Group, LLC10,0000 (0.00%)0.01%$0 MOct 19, 2026
63Barry Investment Advisors, LLC10,0000 (0.00%)0.01%$0 MOct 14, 2026
64Wells Fargo & Company/mn6,500+3,500 (+116.67%)0.01%$0 MNov 16, 2026
65Osaic Holdings, Inc.5,200+1,000 (+23.81%)0.01%$0 MNov 12, 2026
66Fifth Third Bancorp5,0000 (0.00%)0.01%$0 MNov 5, 2026
67Versant Capital Management, Inc3,2570 (0.00%)0.00%$0 MOct 2, 2026
68Royal Bank Of Canada2,456New0.00%$0 MNov 16, 2026
69Global Retirement Partners, LLC2,0000 (0.00%)0.00%$0 MNov 10, 2026
70TD Waterhouse Canada Inc.1,000New0.00%$0 MOct 16, 2026
71Strategic Financial Concepts, LLC596New0.00%$0 MNov 16, 2026
72JPL Wealth Management, LLC500New0.00%$0 MNov 13, 2026
73Rialto Wealth Management, LLC490+31 (+6.75%)0.00%$0 MNov 16, 2026
74Tower Research Capital LLC (TRC)100New0.00%$0 MNov 16, 2026
75Cassaday & Co Wealth Management LLC100New0.00%$0 MOct 27, 2026
76SBI Securities Co., Ltd.54+4 (+8.00%)0.00%$0 MOct 22, 2026
77FMR LLC10 (0.00%)0.00%$0 MNov 10, 2026
78Caitong International Asset Management Co., Ltd1New0.00%$0 MOct 29, 2026

Mutual funds holding Cognition Therapeutics, Inc.#

11 funds hold shares worth $5 M (about 4.7% of the company). Since their previous reports 4 added shares and 4 sold, buying $1 M net.
Mutual funds holding Cognition Therapeutics, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.2.44 M$3 M2.6%<0.01%+19%Jun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.871,598$1 M0.92%<0.01%−0.4%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC416,139$0 M0.44%<0.01%−1.2%May 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors275,235$0 M0.29%0.02%newJun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC143,771$0 M0.15%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC118,702$0 M0.12%<0.01%+5.6%May 31, 2026
🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc.84,940$0 M0.09%<0.01%no changeJul 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC51,054$0 M0.05%<0.01%no changeMay 31, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.38,785$0 M0.04%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.31,797$0 M0.03%<0.01%no changeJun 30, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC18,396$0 M0.02%<0.01%newJun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 11 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Cognition Therapeutics, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$32 K
3 purchases, 3 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$32 K
open market only
Insiders on file
23
since
$32 K$0Mar 2024: bought $10 K (1 trades), sold $0 (0 trades)Mar 24Jan 2025: bought $30 K (1 trades), sold $0 (0 trades)Jan 25Apr 2026: bought $32 K (3 trades), sold $0 (0 trades)Apr
Bought (open market)Sold (open market)Hover a month for the totals
Cognition Therapeutics, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Brett P. MoniaDirectorGrant or award+25,000——73,500Form 4
filed BIOS Memory SPV I, LPDirector, 10% ownerGrant or award+25,000——81,229Form 4
filed Peggy WallaceDirectorGrant or award+25,000——111,461Form 4
filed Jack A. KhattarDirectorGrant or award+25,000——73,500Form 4
filed Ellen B. RichstoneDirectorGrant or award+25,000——83,500Form 4
filed John Brendan DoyleChief Financial OfficerShares withheld for tax-8,567$1.280$11 K618,942Form 4
filed Lisa RicciardiCEO & President, DirectorBuy+9,175$1.100$10 K1.72 MForm 4
filed Anthony CaggianoChief Medical OfficerBuy+10,000$1.110$11 K874,906Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Cognition Therapeutics, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
6.9 M
7.8% of shares · 15.27 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-3.23 reverse split

Trading halts

  • 2024-12-18 14:45 UTC, code LUDP, resumed 14:50 UTC

Fails to deliver

  • : 1,500 shares at $0.74
  • : 4,744 shares at $0.76
  • : 5,144 shares at $0.69
  • : 14,638 shares at $0.73
  • : 5,250 shares at $0.78

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Cognition Therapeutics, Inc. scorecard#

Passes 2 of the 12 checks that could be worked out: strongest in valuation (1 of 4), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation1 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median2.0×Price to book 2.0× against Biotechnology's median of 2.9×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • ✗Free cash flow yield above 5%-40.5%Free cash flow is -40.5% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-0.32 vs -0.86Diluted EPS -0.32 in fiscal 2025 against -0.86 the year before (report's currency).
    • ✗Net income higher than five years earlier-$23 M-$23 M in fiscal 2025 against -$8 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$23 MNet income -$23 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-88.6%-88.6% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities3.5×Current ratio 3.45 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year83.2%Diluted shares up 83.2% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Cognition Therapeutics, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Cognition Therapeutics, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020
Income statement
Research and development374237301913
General and administrative11121413104.5
Operating expenses485451442917
Operating income−48−54−51−44−29−17
Interest expense and finance costs————0.91.8
Net interest income——−0.0−0.0−0.9−1.8
Other non-operating income (expense)24202522179.6
Income tax00000—
Net income attributable to shareholders−23−34−26−21−12−7.8
Earnings per share, basic-0.32-0.86-0.86-0.91-3.13-23.76
Earnings per share, diluted-0.32-0.86-0.86-0.91-3.13-23.76
Shares, weighted average (basic)734030245.20.5
Shares, weighted average (diluted)734030245.20.5
Balance sheet
Cash and cash equivalents37253042555.2
Other current assets————0.00.0
Current assets48303448596.9
Property, plant and equipment0.10.20.30.20.10.2
Right-of-use (leased) assets0.30.50.70.8——
Total assets48303550597.1
Accounts payable1.12.03.73.24.22.0
Current liabilities1411107.87.93.3
Lease liabilities (non-current)0.20.30.50.7——
Total liabilities141111107.920
Retained earnings−199−175−141−115−94−68
Shareholders' equity3419244051−68
Total liabilities and equity48303550597.1
Shares outstanding89603229220.5
Cash-flow statement
Depreciation and amortization0.00.10.10.10.10.1
Share-based compensation2.13.74.43.65.20.5
Cash from operating activities−25−28−16−19−3.6−3.4
Capital expenditure—−0.0−0.1−0.2−0.0−0.0
Cash from investing activities0.0−0.0−0.1−0.2−0.0−0.0
Debt issued—————0.4
Cash from financing activities37244.55.5535.8
Exchange-rate effect on cash——0.0−0.0−0.0−0.0
Change in cash12−4.9−12−13502.3
Report10-K10-K10-K10-K10-K10-K

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Events at Cognition Therapeutics, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling

Delisting notice 1 · Material agreement 2 · Agreement ended 1 · Shareholder vote 2 · Results announced 9

Cognition Therapeutics, Inc.: events reported to the SEC
FiledWhat happenedFiling
Delisting noticeResults announced8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Material agreementAgreement ended8-K
Results announced8-K
Material agreement8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 5, 2026

Acquisitions and funding#

7 private funding rounds before listing

Private share sales · funding history

Private share sales of Cognition Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2018$2 MNo. 7Under $2 million28debt, optionsSEC
Mar 2018$2 MNo. 6$2 to $10 million31debt, optionsSEC
Nov 2016$4 MNo. 5$2 to $10 million50equitySEC
Mar 2016$3 MNo. 4$2 to $10 million41debt, optionsSEC
Mar 2014$16 MNo. 3$10 to $50 million56equitySEC
Dec 2011$2 MNo. 2Under $2 million16equitySEC
Dec 2010$3 MNo. 1$2 to $10 million22equity, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Government contracts: Cognition Therapeutics, Inc.#

No federal contracts in fiscal 2025, and $12.0 M in grants.

Contracts, FY2025
$0
Grants, FY2025
$12.0 M
FY2027 to date
—
contracts and grants
Since FY2008
$74.1 M
contracts and grants
Cognition Therapeutics, Inc.: federal obligations by fiscal year
Fiscal yearContractsGrants
FY2025$0$12.0 M
FY2024$0$13.1 M
FY2023$0$8.5 M
FY2020$0$5.8 M
FY2019$0$11.5 M
FY2018$0$8.2 M
FY2017$0$7.7 M
FY2016$0$5.5 M
FY2015$0$783 K
FY2014$0$700 K
FY2012$0$142 K
FY2010$0$198 K

Source: USAspending.gov. Obligations are binding promises to pay, not payments, and can be negative when an award is cut. Counted under Cognition Therapeutics, Inc.: COGNITION THERAPEUTICS, INC. (UEI NUNHAKQ7MS86)

How Cognition Therapeutics, Inc. compares in Biotechnology

  • Market cap$70 M · higher than 31% of 726
  • Price / book2.0× · lower than 58% of 534
  • FCF yield-40.5% · higher than 28% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Cognition Therapeutics, Inc.🇺🇸$70 M———
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 30, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of March 1, 2026
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, Wikidata, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Cognition Therapeutics, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Cognition Therapeutics, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Cognition Therapeutics, Inc.? Suggest a correction